Login to Your Account

Curevac tops up with $29.5M financing as prostate cancer trial readout nears

By Michael Fitzhugh
Staff Writer

Tuesday, November 8, 2016

Messenger RNA drug developer Curevac AG added $29.5 million in new funds to its coffers from German investors looking to support the home team in a hot field defined by sizable early investments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription